180 Life Sciences (NASDAQ:ATNF) Receives Sell (E+) Rating from Weiss Ratings

Key Points

• 180 Life Sciences has received a "sell (e+)" rating from Weiss Ratings, indicating a continued negative outlook for the company's stock.
• The stock has declined by 28.9%, with a current market capitalization of $45.96 million and a P/E ratio of -0.50.
• Anson Funds Management LP has recently acquired a 7.08% stake in the company, purchasing 225,271 shares valued around $410,000.

Weiss Ratings restated their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF - Free Report) in a research note published on Thursday,Weiss Ratings reports.

180 Life Sciences Stock Performance

ATNF stock traded up $0.37 during trading on Thursday, reaching $7.41. 6,657,000 shares of the company were exchanged, compared to its average volume of 22,030,452. The company has a market cap of $44.76 million, a P/E ratio of -0.49 and a beta of 0.38. 180 Life Sciences has a 52-week low of $0.66 and a 52-week high of $17.75. The stock's 50 day moving average price is $2.39 and its 200 day moving average price is $1.54.

180 Life Sciences (NASDAQ:ATNF - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The company reported ($0.30) EPS for the quarter.

Institutional Trading of 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Anson Funds Management LP bought a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 225,271 shares of the company's stock, valued at approximately $410,000. Anson Funds Management LP owned about 7.08% of 180 Life Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 4.07% of the company's stock.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.